Report Content
Chapter 1 Methodology
1.1 Methodology
1.2 Market definitions
1.3 Forecast parameters
1.4 Data sources
1.4.1 Secondary
1.4.1.1 Paid sources
1.4.1.2 Unpaid sources
1.4.2 Primary
Chapter 2 Executive Summary
2.1 Outpatient oncology infusion industry 360° synopsis, 2017 - 2030
2.1.1 Business trends
2.1.2 Product trends
2.1.3 Application trends
2.1.4 Therapy trends
2.1.5 Mode trends
2.1.6 Regional trends
Chapter 3 Outpatient Oncology Infusion Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2017 - 2030
3.3 Industry impact forces
3.3.1 Growth drivers
3.3.1.1 Recent technological advancements in infusion pumps
3.3.1.2 Rising prevalence of cancer across the globe
3.3.1.3 Surging government initiatives for cancer awareness
3.3.2 Industry pitfalls & challenges
3.3.2.1 High costs of cancer therapies
3.3.2.2 Safety concern associated with the cancer therapy
3.4 Growth potential analysis
3.4.1 By product
3.4.2 By application
3.4.3 By therapy
3.4.4 By mode
3.5 COVID-19 impact analysis
3.6 Porter’s analysis
3.7 Competitive landscape, 2021
3.8 PESTEL analysis
Chapter 4 Outpatient Oncology Infusion Market, By Product
4.1 Key segment trends
4.2 Infusion Pumps
4.2.1 Market size, by region, 2017 - 2030 (USD Million)
4.3 Intravenous Sets
4.3.1 Market size, by region, 2017 - 2030 (USD Million)
4.4 IV Cannulas
4.4.1 Market size, by region, 2017 - 2030 (USD Million)
4.5 Needleless Connectors
4.5.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 5 Outpatient Oncology Infusion Market, By Application
5.1 Key segment trends
5.2 Lung Cancer
5.2.1 Market size, by region, 2017 - 2030 (USD Million)
5.3 Liver Cancer
5.3.1 Market size, by region, 2017 - 2030 (USD Million)
5.4 Breast Cancer
5.4.1 Market size, by region, 2017 - 2030 (USD Million)
5.5 Prostate Cancer
5.5.1 Market size, by region, 2017 - 2030 (USD Million)
5.6 Other
5.6.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 6 Outpatient Oncology Infusion Market, By Therapy
6.1 Key segment trends
6.2 Chemotherapy
6.2.1 Market size, by region, 2017 - 2030 (USD Million)
6.3 Targeted Therapy
6.3.1 Market size, by region, 2017 - 2030 (USD Million)
6.4 Immunotherapy
6.4.1 Market size, by region, 2017 - 2030 (USD Million)
6.5 Hormonal Therapy
6.5.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 7 Outpatient Oncology Infusion Market, By Mode
7.1 Key segment trends
7.2 Intramuscular (IM)
7.2.1 Market size, by region, 2017 - 2030 (USD Million)
7.3 Intravenous (IV)
7.3.1 Market size, by region, 2017 - 2030 (USD Million)
7.4 Subcutaneous
7.4.1 Market size, by region, 2017 - 2030 (USD Million)
7.5 Others
7.5.1 Market size, by region, 2017 - 2030 (USD Million)
Chapter 8 Outpatient Oncology Infusion Market, By Region
8.1 Key regional trends
8.2 North America
8.2.1 Market size, by country, 2017 - 2030 (USD Million)
8.2.2 Market size, by product, 2017 - 2030 (USD Million)
8.2.3 Market size, by application, 2017 - 2030 (USD Million)
8.2.4 Market size, by therapy, 2017 - 2030 (USD Million)
8.2.5 Market size, by mode, 2017 - 2030 (USD Million)
8.2.6 U.S.
8.2.6.1 Market size, by product, 2017 - 2030 (USD Million)
8.2.6.2 Market size, by application, 2017 - 2030 (USD Million)
8.2.6.3 Market size, by therapy, 2017 - 2030 (USD Million)
8.2.6.4 Market size, by mode, 2017 - 2030 (USD Million)
8.2.7 Canada
8.2.7.1 Market size, by product, 2017 - 2030 (USD Million)
8.2.7.2 Market size, by application, 2017 - 2030 (USD Million)
8.2.7.3 Market size, by therapy, 2017 - 2030 (USD Million)
8.2.7.4 Market size, by mode, 2017 - 2030 (USD Million)
8.3 Europe
8.3.1 Market size, by country, 2017 - 2030 (USD Million)
8.3.2 Market size, by product, 2017 - 2030 (USD Million)
8.3.3 Market size, by application, 2017 - 2030 (USD Million)
8.3.4 Market size, by therapy, 2017 - 2030 (USD Million)
8.3.5 Market size, by mode, 2017 - 2030 (USD Million)
8.3.6 Germany
8.3.6.1 Market size, by product, 2017 - 2030 (USD Million)
8.3.6.2 Market size, by application, 2017 - 2030 (USD Million)
8.3.6.3 Market size, by therapy, 2017 - 2030 (USD Million)
8.3.6.4 Market size, by mode, 2017 - 2030 (USD Million)
8.3.7 UK
8.3.7.1 Market size, by product, 2017 - 2030 (USD Million)
8.3.7.2 Market size, by application, 2017 - 2030 (USD Million)
8.3.7.3 Market size, by therapy, 2017 - 2030 (USD Million)
8.3.7.4 Market size, by mode, 2017 - 2030 (USD Million)
8.3.8 France
8.3.8.1 Market size, by product, 2017 - 2030 (USD Million)
8.3.8.2 Market size, by application, 2017 - 2030 (USD Million)
8.3.8.3 Market size, by therapy, 2017 - 2030 (USD Million)
8.3.8.4 Market size, by mode, 2017 - 2030 (USD Million)
8.3.9 Spain
8.3.9.1 Market size, by product, 2017 - 2030 (USD Million)
8.3.9.2 Market size, by application, 2017 - 2030 (USD Million)
8.3.9.3 Market size, by therapy, 2017 - 2030 (USD Million)
8.3.9.4 Market size, by mode, 2017 - 2030 (USD Million)
8.4 Asia Pacific
8.4.1 Market size, by country, 2017 - 2030 (USD Million)
8.4.2 Market size, by product, 2017 - 2030 (USD Million)
8.4.3 Market size, by application, 2017 - 2030 (USD Million)
8.4.4 Market size, by therapy, 2017 - 2030 (USD Million)
8.4.5 Market size, by mode, 2017 - 2030 (USD Million)
8.4.6 Japan
8.4.6.1 Market size, by product, 2017 - 2030 (USD Million)
8.4.6.2 Market size, by application, 2017 - 2030 (USD Million)
8.4.6.3 Market size, by therapy, 2017 - 2030 (USD Million)
8.4.6.4 Market size, by mode, 2017 - 2030 (USD Million)
8.4.7 China
8.4.7.1 Market size, by product, 2017 - 2030 (USD Million)
8.4.7.2 Market size, by application, 2017 - 2030 (USD Million)
8.4.7.3 Market size, by therapy, 2017 - 2030 (USD Million)
8.4.7.4 Market size, by mode, 2017 - 2030 (USD Million)
8.4.8 India
8.4.8.1 Market size, by product, 2017 - 2030 (USD Million)
8.4.8.2 Market size, by application, 2017 - 2030 (USD Million)
8.4.8.3 Market size, by therapy, 2017 - 2030 (USD Million)
8.4.8.4 Market size, by mode, 2017 - 2030 (USD Million)
8.4.9 Australia
8.4.9.1 Market size, by product, 2017 - 2030 (USD Million)
8.4.9.2 Market size, by application, 2017 - 2030 (USD Million)
8.4.9.3 Market size, by therapy, 2017 - 2030 (USD Million)
8.4.9.4 Market size, by mode, 2017 - 2030 (USD Million)
8.5 Latin America
8.5.1 Market size, by country, 2017 - 2030 (USD Million)
8.5.2 Market size, by product, 2017 - 2030 (USD Million)
8.5.3 Market size, by application, 2017 - 2030 (USD Million)
8.5.4 Market size, by therapy, 2017 - 2030 (USD Million)
8.5.5 Market size, by mode, 2017 - 2030 (USD Million)
8.5.6 Brazil
8.5.6.1 Market size, by product, 2017 - 2030 (USD Million)
8.5.6.2 Market size, by application, 2017 - 2030 (USD Million)
8.5.6.3 Market size, by therapy, 2017 - 2030 (USD Million)
8.5.6.4 Market size, by mode, 2017 - 2030 (USD Million)
8.5.7 Mexico
8.5.7.1 Market size, by product, 2017 - 2030 (USD Million)
8.5.7.2 Market size, by application, 2017 - 2030 (USD Million)
8.5.7.3 Market size, by therapy, 2017 - 2030 (USD Million)
8.5.7.4 Market size, by mode, 2017 - 2030 (USD Million)
8.6 MEA
8.6.1 Market size, by country, 2017 - 2030 (USD Million)
8.6.2 Market size, by product, 2017 - 2030 (USD Million)
8.6.3 Market size, by application, 2017 - 2030 (USD Million)
8.6.4 Market size, by therapy, 2017 - 2030 (USD Million)
8.6.5 Market size, by mode, 2017 - 2030 (USD Million
8.6.6 South Africa
8.6.6.1 Market size, by product, 2017 - 2030 (USD Million)
8.6.6.2 Market size, by application, 2017 - 2030 (USD Million)
8.6.6.3 Market size, by therapy, 2017 - 2030 (USD Million)
8.6.6.4 Market size, by mode, 2017 - 2030 (USD Million)
8.6.7 Saudi Arabia
8.6.7.1 Market size, by product, 2017 - 2030 (USD Million)
8.6.7.2 Market size, by application, 2017 - 2030 (USD Million)
8.6.7.3 Market size, by therapy, 2017 - 2030 (USD Million)
8.6.7.4 Market size, by mode, 2017 - 2030 (USD Million)
Chapter 9 Company Profiles
9.1 Strategy dashboard, 2021
9.2 B. Braun Melsungen AG
9.2.1 Business overview
9.2.2 Financial data
9.2.3 Product landscape
9.2.4 Strategic outlook
9.2.5 SWOT analysis
9.3 Baxter
9.3.1 Business overview
9.3.2 Financial data
9.3.3 Product landscape
9.3.4 Strategic outlook
9.3.5 SWOT analysis
9.4 Becton, Dickinson, and Company
9.4.1 Business overview
9.4.2 Financial data
9.4.3 Product landscape
9.4.4 Strategic outlook
9.4.5 SWOT analysis
9.5 Fresenius Kabi
9.5.1 Business overview
9.5.2 Financial data
9.5.3 Product landscape
9.5.4 Strategic outlook
9.5.5 SWOT analysis
9.6 ICU Medical, Inc
9.6.1 Business overview
9.6.2 Financial data
9.6.3 Product landscape
9.6.4 Strategic outlook
9.6.5 SWOT analysis
9.7 IRadimed Corporation
9.7.1 Business overview
9.7.2 Financial data
9.7.3 Product landscape
9.7.4 Strategic outlook
9.7.5 SWOT analysis
9.8 Nipro Corporation
9.8.1 Business overview
9.8.2 Financial data
9.8.3 Product landscape
9.8.4 Strategic outlook
9.8.5 SWOT analysis
9.9 Terumo Corporation
9.9.1 Business overview
9.9.2 Financial data
9.9.3 Product landscape
9.9.4 Strategic outlook
9.9.5 SWOT analysis
9.10 Smiths Medical
9.10.1 Business overview
9.10.2 Financial data
9.10.3 Product landscape
9.10.4 Strategic outlook
9.10.5 SWOT analysis
9.11 Medtronic PLC
9.11.1 Business overview
9.11.2 Financial data
9.11.3 Product landscape
9.11.4 Strategic outlook
9.11.5 SWOT analysis
9.12 Roche Diagnostics
9.12.1 Business overview
9.12.2 Financial data
9.12.3 Product landscape
9.12.4 Strategic outlook
9.12.5 SWOT analysis
9.13 Teleflex, Inc.,
9.13.1 Business overview
9.13.2 Financial data
9.13.3 Product landscape
9.13.4 Strategic outlook
9.13.5 SWOT analysis
